ClearShift Health
Healthcare Workforce Technology & Per-Diem Staffing Marketplace
Company Overview
ClearShift Health is a Nashville-based healthcare workforce technology company operating a dual-sided marketplace connecting healthcare facilities with per-diem and contract clinical staff. Founded in 2017, the Company has grown from a regional per-diem staffing tool to a multi-state platform serving 312 facilities across 34 states, with over 14,200 credentialed clinicians in its marketplace. The Company raised a $22M Series B in Q3 2022 and has deployed that capital into geographic expansion, enterprise sales infrastructure, and platform development. ClearShift's core value proposition — eliminating agency markup through direct facility-to-clinician matching — has proven compelling in the SMB and community hospital segment, where the Company has achieved strong penetration and retention. The critical strategic question now is whether the Company can successfully navigate the transition from SMB-led growth to enterprise-led growth before its Series B capital is fully deployed.
Dimension Scorecard
"Fast-growing healthcare staffing platform hitting a growth inflection — decelerating from 50% to 21%, sales motion misaligned with enterprise segment, CS leadership instability creating hidden churn risk."
Table of Contents
This report integrates ten analytical dimensions to produce a comprehensive directional assessment. Each section is independently substantive and cross-referenced throughout the analysis.
Five-year revenue trajectory, EBITDA margins, cash flow analysis, SaaS metrics, and LTV:CAC ratios.
Technology stack assessment, platform performance benchmarking, integration coverage, and engineering capacity analysis.
Headcount by function, leadership team assessment, attrition analysis, and organizational design evaluation.
Digital channel performance, SEO trajectory, content authority, brand positioning, and demand generation effectiveness.
Pipeline metrics, win rates, quota attainment, sales cycle analysis, and revenue generation efficiency.
Cross-dimensional vulnerability analysis identifying organizational risks invisible in single-dimension assessments.
Named competitor analysis, relative positioning, differentiation assessment, and market share dynamics.
Strategic marketability scoring across six dimensions, buyer universe mapping, and estimated valuation range.
Three-scenario financial projections (FY2025–FY2027), momentum scorecard, and directional risk assessment.
Prioritized intervention plan with timelines, investment requirements, expected impact, and conclusion.
Financial Performance & Trending
ClearShift's financial trajectory reflects the classic pattern of a venture-backed marketplace business transitioning from early hypergrowth to a more complex growth phase. Revenue has grown from $5.2M in FY2020 to $21.4M in FY2024, representing a 5-year CAGR of approximately 32%. However, the growth rate has decelerated meaningfully — from 50% YoY in FY2022 to 31% in FY2023 to 21% in FY2024 — and the Company has not yet achieved EBITDA profitability. The EBITDA loss has narrowed from -$4.1M in FY2022 (peak investment year) to -$1.2M in FY2024, reflecting improving unit economics as the platform scales. The Company's gross margin has expanded from 58% to 67% over the period, driven by the shift from lower-margin staffing transactions to higher-margin SaaS subscription revenue. The key financial risk is the burn rate relative to remaining Series B capital: at the current cash consumption rate of approximately $1.8M per year (operating losses plus capex), the Company has approximately 18–22 months of runway before requiring additional capital.
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Total Revenue | $5.2M | $7.8M | $11.7M | $15.3M | $21.4M |
| YoY Growth | — | 50% | 50% | 31% | 21% |
| Gross Profit | $3.0M | $4.7M | $7.3M | $10.1M | $14.3M |
| Gross Margin | 58% | 60% | 62% | 66% | 67% |
| EBITDA | -$1.8M | -$2.9M | -$4.1M | -$2.8M | -$1.2M |
| EBITDA Margin | -35% | -37% | -35% | -18% | -5.6% |
| SaaS ARR | $1.1M | $2.4M | $4.8M | $7.2M | $10.8M |
| Marketplace GMV | $18M | $28M | $44M | $58M | $78M |
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Net Revenue Retention (NRR) | 104% | 108% | 112% | 109% | 106% |
| Gross Revenue Retention (GRR) | 88% | 90% | 91% | 89% | 87% |
| Annual Client Churn | 12% | 10% | 9% | 11% | 13% |
| Average Contract Value (ACV) | $16.7K | $19.2K | $22.4K | $26.8K | $34.6K |
| Marketplace Take Rate | 14.2% | 14.8% | 15.1% | 15.4% | 15.8% |
| LTV:CAC Ratio | 2.8x | 3.2x | 3.6x | 3.1x | 2.7x |
ClearShift's financial trajectory shows a company approaching an inflection point. The deceleration from 50% to 21% growth, combined with the approaching end of Series B runway, creates a 12–18 month window in which the Company must either demonstrate a credible path to profitability or raise additional capital at potentially dilutive terms. The improving gross margin (67%) and narrowing EBITDA loss (-5.6%) provide a positive foundation, but the declining LTV:CAC ratio (3.6x to 2.7x) signals that growth is becoming more expensive as the Company moves upmarket.
Technical Capabilities & Infrastructure
ClearShift has invested meaningfully in its technology platform since the Series B, transitioning from a primarily marketplace-oriented application to a more comprehensive workforce management system. The core platform is built on a modern React/Node.js stack with AWS infrastructure, and the Company has made notable investments in mobile-first design (the clinician-facing app has 4.6 stars across 2,800+ reviews), credential verification automation, and real-time scheduling algorithms. The primary technical gap is in enterprise integration capabilities: the platform currently supports only basic HL7 FHIR integrations with hospital EHR systems, and the absence of deep Epic and Cerner integration is a meaningful barrier to enterprise conversion. The Company's AI/ML capabilities are nascent — a predictive scheduling feature was launched in Q4 2024 but has limited adoption. Infrastructure reliability is strong (99.7% uptime), and the engineering team has grown from 12 to 34 engineers since the Series B.
| Component | Technology | Status | Notes |
|---|---|---|---|
| Frontend (Web) | React 18, TypeScript, Tailwind CSS | Current | Modern stack; facility-facing dashboard well-regarded |
| Mobile App (Clinician) | React Native (iOS/Android) | Current | 4.6★ App Store; 2,800+ reviews; primary clinician touchpoint |
| Backend API | Node.js, Express, GraphQL | Current | Microservices architecture; good scalability foundation |
| Infrastructure | AWS (EKS, RDS, ElastiCache) | Current | Multi-AZ; 99.7% uptime; SOC 2 Type II certified |
| EHR Integration | HL7 FHIR (limited) | Below Market | No Epic/Cerner deep integration; key enterprise barrier |
| AI/ML Capabilities | Custom ML (predictive scheduling) | Early Stage | Q4 2024 launch; limited adoption; roadmap promising |
| Credential Verification | Proprietary + Nursys API | Competitive | Automated; 48-hr avg verification; differentiator |
| Payments/Payroll | Stripe + ADP integration | Adequate | Same-day pay capability; clinician satisfaction driver |
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | Benchmark |
|---|---|---|---|---|---|---|
| Platform Uptime | 99.4% | 99.5% | 99.6% | 99.7% | 99.7% | 99.9% (enterprise) |
| Mobile App Rating (iOS) | 4.3★ | 4.4★ | 4.5★ | 4.6★ | 4.6★ | 4.5★ (category avg) |
| Avg Credential Verify Time | 5.2 days | 3.8 days | 2.4 days | 52 hrs | 48 hrs | 24 hrs (best-in-class) |
| API Response Time (p95) | 320ms | 280ms | 240ms | 195ms | 180ms | 200ms (target) |
| EHR Integrations Active | 2 | 4 | 6 | 8 | 11 | 25+ (enterprise req.) |
ClearShift's technology platform is strong in the areas that matter most to its current SMB customer base — mobile experience, credential automation, and scheduling reliability. The critical gap is in enterprise integration depth: without native Epic and Cerner integrations, the Company cannot win enterprise health system contracts that require seamless EHR workflow integration. This gap is addressable but requires 12–18 months of focused engineering investment.
Personnel Effectiveness & Organizational Capacity
ClearShift's personnel profile reflects the tension inherent in a company transitioning from startup to scale-up. The Company has grown from 62 FTE at Series B close to 187 FTE today, adding significant headcount in sales (from 8 to 31 reps), engineering (from 12 to 34), and client success (from 6 to 22). The quality of the leadership team is mixed: the CEO and CTO are strong and have navigated the growth phase effectively, but the VP of Client Success role has turned over twice in 18 months — a pattern that creates institutional knowledge loss and client relationship instability at exactly the moment when enterprise retention is most critical. The sales organization has been restructured to add an enterprise sales team (4 AEs), but the enterprise AEs lack healthcare-specific domain expertise, and the sales cycle has extended from 45 days (SMB) to 180+ days (enterprise) without corresponding adjustments to sales process or compensation structure.
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Total FTE | 38 | 62 | 118 | 156 | 187 |
| Engineering & Product | 8 | 12 | 22 | 28 | 34 |
| Sales & Marketing | 5 | 8 | 18 | 24 | 31 |
| Client Success | 4 | 6 | 12 | 18 | 22 |
| G&A / Operations | 21 | 36 | 66 | 86 | 100 |
| Revenue per FTE | $137K | $126K | $99K | $98K | $114K |
| Annual Turnover Rate | 18% | 21% | 24% | 26% | 22% |
| Role | Name | Tenure | Assessment |
|---|---|---|---|
| CEO | Marcus Webb | 7 years (Founder) | Strong operator; healthcare domain expertise; Series B execution effective; needs enterprise sales coaching |
| CTO | Priya Nair | 5 years | Excellent technical leader; modern architecture decisions; enterprise integration roadmap needs acceleration |
| CFO | David Okonkwo | 2.5 years | Solid financial discipline; Series C preparation underway; runway management appropriate |
| VP Sales | Jennifer Castillo | 14 months | Strong SMB background; enterprise motion still developing; compensation structure misaligned with 180-day cycles |
| VP Client Success | VACANT (2nd in 18 mo.) | Vacant — 60 days | CRITICAL RISK: Second VP CS departure in 18 months; institutional knowledge loss; enterprise retention at risk |
| VP Marketing | Thomas Reyes | 3 years | Strong demand gen; content strategy effective; brand positioning needs enterprise-tier refinement |
The VP of Client Success vacancy is the single highest-priority personnel risk in this assessment. Two CS leadership departures in 18 months, during a period when the Company is actively expanding into enterprise accounts that require dedicated success resources, creates a compounding retention risk. The enterprise AEs currently closing deals have no CS counterpart to hand off to, and the interim CS team lacks the authority and resources to execute enterprise onboarding programs. This must be resolved within 60 days.
Marketing Impact & Digital Presence Analysis
ClearShift's marketing function has been a meaningful competitive advantage in the SMB segment, where the Company's content-led strategy and strong SEO presence have driven consistent inbound pipeline. The Company ranks in the top 3 organic positions for 'per diem nursing platform,' 'healthcare shift marketplace,' and 'travel nurse alternative' — high-intent search terms that drive qualified facility and clinician leads. The Capterra and G2 review profiles are strong (4.5★ and 4.4★ respectively), and the Company's NPS of 52 is above the healthcare technology category average. The marketing gap is in enterprise-tier positioning: the Company's brand and messaging are optimized for SMB buyers, and the transition to enterprise requires a distinct content strategy, case study library, and analyst relations program that has not yet been built.
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Monthly Organic Visitors | 18,400 | 28,600 | 42,100 | 58,300 | 71,200 |
| Domain Authority (Moz) | 34 | 38 | 42 | 46 | 49 |
| Capterra Rating | 4.2★ | 4.3★ | 4.5★ | 4.5★ | 4.5★ |
| G2 Rating | 4.1★ | 4.2★ | 4.4★ | 4.4★ | 4.4★ |
| Net Promoter Score (NPS) | 38 | 44 | 49 | 51 | 52 |
| Inbound MQL Volume/Mo. | 42 | 68 | 104 | 138 | 162 |
| Inbound-to-Demo Rate | 28% | 31% | 34% | 32% | 30% |
| Content Pieces Published/Mo. | 6 | 8 | 12 | 14 | 16 |
ClearShift's marketing engine is well-calibrated for SMB acquisition and has built a strong organic foundation. The declining inbound-to-demo conversion rate (34% to 30%) is an early signal that the inbound mix is shifting toward less-qualified traffic as the Company's content volume increases. The enterprise marketing gap — no dedicated enterprise content, no analyst relations, no reference customer program — must be addressed in parallel with the enterprise sales build-out.
Sales Activity & Revenue Generation
ClearShift's sales performance reflects the dual-speed reality of a company operating two distinct go-to-market motions simultaneously. The SMB motion is efficient and well-tuned: the 8 SMB AEs each close an average of 3.2 new accounts per month at an average ACV of $18K, with a 45-day sales cycle and 68% win rate. The enterprise motion is nascent and underperforming: the 4 enterprise AEs have collectively closed only 7 enterprise accounts in their first 12 months, against a target of 24, with an average sales cycle of 187 days and a 22% win rate. The enterprise underperformance is attributable to three factors: (1) the enterprise AEs lack healthcare system procurement experience; (2) the absence of deep EHR integration is a disqualifying factor in approximately 40% of enterprise evaluations; and (3) the Company does not have reference customers in the enterprise segment, creating a credibility gap in competitive evaluations.
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| New Logos (Total) | 48 | 72 | 108 | 124 | 138 |
| New Logos (SMB) | 48 | 72 | 104 | 116 | 131 |
| New Logos (Enterprise) | 0 | 0 | 4 | 8 | 7 |
| SMB Win Rate | 62% | 65% | 68% | 67% | 68% |
| Enterprise Win Rate | — | — | 35% | 28% | 22% |
| Avg SMB Sales Cycle | 52 days | 48 days | 45 days | 44 days | 45 days |
| Avg Enterprise Sales Cycle | — | — | 142 days | 168 days | 187 days |
| Quota Attainment (SMB AEs) | 72% | 78% | 82% | 79% | 81% |
| Quota Attainment (Ent. AEs) | — | — | 68% | 42% | 29% |
| Net Revenue Retention | 104% | 108% | 112% | 109% | 106% |
The enterprise sales motion is in distress. Enterprise AE quota attainment has collapsed from 68% in the first year to 29% in FY2024, and the win rate has declined from 35% to 22% as the Company encounters more sophisticated competitive evaluations. Without intervention — specifically, EHR integration depth, reference customer development, and enterprise AE coaching — the enterprise motion will continue to underperform and drain resources from the more productive SMB motion.
Hidden Weakness Discovery Framework
Trajectory Analysis™ goes beyond surface-level metrics to identify ecosystem vulnerabilities — organizational weaknesses that emerge from the interaction between different business dimensions rather than weakness in any single area. These hidden vulnerabilities are the most consequential findings of this assessment.
CS Leadership Instability Creating Hidden Enterprise Churn Risk
The second VP of Client Success departure in 18 months has created an organizational vacuum at the precise moment when ClearShift is onboarding its first enterprise accounts. Enterprise clients require dedicated success resources, structured QBR programs, and executive-level relationship management — none of which are being delivered consistently under the current interim CS structure. The 7 enterprise accounts closed in FY2024 are at elevated churn risk: without a VP CS to build the enterprise success playbook, these accounts are receiving the same SMB-tier service model that is insufficient for their complexity. Analysis of the Company's churn data shows that clients who do not complete a structured 90-day onboarding program churn at 3.4x the rate of those who do — and the current CS team is completing structured onboarding for only 31% of new enterprise accounts.
Hire VP of Client Success within 45 days — prioritize candidates with enterprise healthcare SaaS CS experience. Implement an emergency enterprise account stabilization program: assign a dedicated CSM to each of the 7 enterprise accounts, schedule executive check-ins within 30 days, and complete a formal health assessment for each account. Build the enterprise success playbook (onboarding, QBR, expansion) in parallel with the VP CS search.
Enterprise Sales Motion Misaligned with Enterprise Buyer Requirements
ClearShift's enterprise sales motion was built by promoting the existing SMB sales process rather than designing a purpose-built enterprise go-to-market. The result is a mismatch between what enterprise health system buyers require and what ClearShift's sales team is equipped to deliver. Enterprise health system procurement involves clinical informatics teams, IT security reviews, legal/compliance evaluation, and C-suite sponsorship — none of which the current enterprise AE team has experience navigating. The 40% disqualification rate due to EHR integration gaps compounds this problem: the sales team is spending significant time on opportunities that are structurally unwinnable with the current product.
Hire 1–2 enterprise AEs with specific health system procurement experience. Develop an enterprise-specific sales playbook that maps to health system buying processes. Prioritize Epic and Cerner integration on the product roadmap to eliminate the 40% structural disqualification. Create a reference customer program: offer the 7 existing enterprise accounts enhanced terms in exchange for reference participation.
Growth Deceleration Approaching Series C Fundraising Window
ClearShift's growth rate has decelerated from 50% to 21% over the past two years, and the Company is approximately 18 months from needing to raise a Series C. Venture investors evaluating a Series C will scrutinize the growth trajectory carefully: a company raising at 21% growth with a declining LTV:CAC ratio (3.6x to 2.7x) will face a more challenging fundraising environment than one raising at 30%+ growth with stable unit economics. The deceleration is partly structural (the SMB market is becoming more penetrated) and partly addressable (the enterprise motion is underperforming its potential). The risk is that the Company enters the Series C fundraising process with a growth rate that does not support a premium valuation.
Implement a 90-day growth acceleration initiative: (1) reactivate the 48 churned accounts from FY2023–2024 with a win-back campaign; (2) launch an expansion revenue program targeting existing SMB accounts for upsell to the premium tier; (3) accelerate the enterprise pipeline by addressing the EHR integration gap. Target: return to 28%+ growth rate before initiating Series C process.
Competitive Intelligence & Market Positioning
The healthcare workforce technology market has experienced significant consolidation and investment since 2020, driven by the COVID-19 pandemic's exposure of critical staffing vulnerabilities in healthcare systems. ClearShift competes in a market that has attracted over $2B in venture investment since 2021, and several well-funded competitors have emerged with capabilities that challenge ClearShift's positioning in different segments. The Company's core competitive advantage — its direct marketplace model that eliminates agency markup — remains compelling, but the advantage is eroding as larger platforms replicate the model with greater capital resources.
| Competitor | Est. Revenue | Primary Strength | ClearShift Advantage / Risk |
|---|---|---|---|
| Trusted Health | $180M+ (est.) | Travel nurse marketplace; brand recognition; $200M+ raised | ClearShift: per-diem focus; lower cost structure; facility-side UX |
| Clipboard Health | $300M+ (est.) | Per-diem nursing; aggressive pricing; $500M+ raised | ClearShift: credential automation; enterprise features; retention |
| ShiftMed | $120M (est.) | Per-diem + W2 hybrid; payroll integration | ClearShift: mobile UX; marketplace liquidity; NPS advantage |
| Aya Healthcare | $1.5B+ | Full-service staffing; enterprise relationships; scale | ClearShift: technology-first; lower markup; direct model |
| Nomad Health | $85M (est.) | Travel + per-diem; $200M raised; physician coverage | ClearShift: facility-side workflow integration; per-diem depth |
| IntelyCare | $150M (est.) | LTC/SNF focus; W2 model; AI scheduling | ClearShift: broader facility types; marketplace model |
ClearShift occupies a defensible mid-market position but faces capital asymmetry risk from better-funded competitors. Clipboard Health's $500M+ in funding gives it the ability to sustain below-cost pricing in contested markets for an extended period. ClearShift's response must be to deepen its moat in areas where capital cannot easily replicate its advantage: credential automation depth, facility workflow integration, and enterprise-tier service quality.
Marketability Assessment & Strategic Value Analysis
ClearShift Health presents a compelling but time-sensitive investment or acquisition opportunity. The Company's strategic assets — a credentialed clinician marketplace with genuine liquidity, a modern technology platform, and strong brand recognition in the per-diem nursing segment — are genuinely valuable and difficult to replicate. The current challenges (enterprise motion underperformance, CS leadership gap, growth deceleration) are addressable with focused management attention and modest capital investment. The optimal transaction window is 18–24 months: sufficient time to demonstrate enterprise motion improvement and approach EBITDA breakeven, but before the Series C fundraising process creates competitive dynamics that complicate strategic conversations.
| Assessment Area | Score | Rating | Key Finding |
|---|---|---|---|
| Revenue Quality & Stability | 6/10 | Adequate | 21% YoY growth; 87% GRR; NRR 106%; deceleration trend requires monitoring |
| Product Competitiveness | 7/10 | Positive | Strong mobile UX; credential automation differentiator; EHR integration gap limits enterprise |
| Financial Performance | 5/10 | Adequate | Approaching breakeven; 18-22 month runway; improving unit economics; Series C required |
| Technology Infrastructure | 7/10 | Positive | Modern stack; SOC 2 certified; EHR integration depth is primary gap |
| Personnel Effectiveness | 5/10 | Adequate | Strong CEO/CTO; VP CS vacancy is critical risk; enterprise AE underperformance |
| Marketing & Digital Presence | 8/10 | Strong | Top-3 organic rankings; 4.5★ reviews; strong NPS; enterprise positioning gap |
| Sales Performance | 6/10 | Adequate | SMB motion excellent; enterprise motion underperforming; dual-speed challenge |
| Strategic Asset Value | 8/10 | Strong | 14,200+ credentialed clinicians; 312 facility relationships; marketplace liquidity moat |
Trajectory Projections & Momentum Analysis
| Scenario | FY2025E Rev | FY2026E Rev | FY2027E Rev | FY2025E EBITDA | FY2026E EBITDA | FY2027E EBITDA |
|---|---|---|---|---|---|---|
| Continue Current Trajectory | $25.8M | $29.4M | $32.8M | -$0.4M | $1.8M | $3.9M |
| Accelerated Enterprise Build | $27.2M | $34.6M | $44.8M | -$1.2M | $2.4M | $7.2M |
| Strategic Acquisition (Optimized) | $27.2M | $38.4M | $54.2M | -$0.8M | $4.8M | $12.4M |
Growth decelerating but unit economics improving; enterprise motion requires urgent attention
Approaching breakeven; improving margins; runway adequate but Series C timing critical
Modern platform; strong mobile; EHR integration gap is primary technical risk
VP CS vacancy is highest-priority risk; enterprise AE underperformance requires coaching
Best-in-class organic presence; strong review profile; enterprise positioning gap
SMB motion excellent; enterprise motion in distress; dual-speed challenge
Defensible mid-market position; capital asymmetry risk from Clipboard Health
Marketplace liquidity moat; credentialed clinician network; facility relationships
Strategic Implementation Framework
| Priority | Intervention | Timeline | Investment | Expected Impact |
|---|---|---|---|---|
| URGENT — #1 | Hire VP of Client Success with enterprise healthcare SaaS experience | 0–45 days | $180–220K base | Eliminates highest-priority churn risk; enables enterprise success playbook; stabilizes 7 enterprise accounts |
| URGENT — #2 | Emergency enterprise account stabilization: assign dedicated CSMs, schedule executive check-ins, complete health assessments | 0–30 days | $40K CS investment | Protects $2.8M ARR in enterprise accounts; reduces near-term churn risk |
| Critical — #3 | Accelerate Epic & Cerner integration development — eliminate 40% structural disqualification in enterprise evaluations | Q2–Q3 2025 | $380K engineering | Expands addressable enterprise market by ~60%; improves win rate from 22% toward 40% |
| Critical — #4 | Hire 2 enterprise AEs with health system procurement experience; restructure enterprise compensation for 180-day cycles | 0–60 days | $320K total comp | Rebuilds enterprise pipeline credibility; improves quota attainment from 29% toward 65% |
| High — #5 | Launch reference customer program: offer enhanced terms to 7 enterprise accounts in exchange for reference participation | 0–45 days | $60K in concessions | Creates social proof for enterprise sales; improves win rate; accelerates pipeline velocity |
| High — #6 | Implement expansion revenue program: upsell existing 312 SMB accounts to premium tier | Q2 2025 | $80K marketing | Targets $1.2M incremental ARR; improves NRR from 106% toward 115%; accelerates growth rate |
| Medium — #7 | Build enterprise-specific content and analyst relations program (KLAS, Black Book rankings) | Q2–Q3 2025 | $120K marketing | Establishes enterprise brand credibility; supports 12-month Series C preparation narrative |
ClearShift Health is a genuinely strong business facing a genuinely difficult transition. The Company has built something rare in healthcare technology: a two-sided marketplace with real liquidity, a modern platform that clinicians and facilities actually prefer to use, and a brand that commands respect in its core segment. The challenges it faces — enterprise motion underperformance, CS leadership instability, and growth deceleration — are real but addressable. The window for addressing them is 12–18 months. Smith Partners recommends a focused intervention program that prioritizes the VP CS hire and enterprise account stabilization above all else, followed by the EHR integration investment that will unlock the enterprise market. With these interventions in place, ClearShift is well-positioned to execute a Series C at a premium valuation or pursue a strategic transaction with a healthcare system, staffing company, or enterprise software platform that values its marketplace assets.
Index of Figures, Tables & Key Terms
The Trajectory Analysis™ framework evaluates companies across five primary dimensions — Financial Performance, Technical Capabilities, Personnel Effectiveness, Marketing Impact, and Sales Activity — each scored on a 0–10 scale. Dimension scores are synthesized into an overall Trajectory Score that reflects directional momentum rather than static position. The Hidden Weakness Discovery Framework applies cross-dimensional analysis to identify organizational vulnerabilities that are invisible in single-dimension assessments. All financial data reflects management-reported figures for FY2020–FY2024. Projections are scenario-based estimates and do not constitute a guarantee of future performance. This report is prepared exclusively for authorized recipients and is subject to the confidentiality obligations set forth in the engagement agreement.
Ready to see your own Trajectory?
The Trajectory Report™ reveals where your business is truly headed — across five dimensions — and what to do about it. Let's start the conversation.